Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs

Does Steve Nissen, an outspoken critic of inappropriate industry influence in medicine, have his own conflict of interest problem? This week Nissen, the chief of cardiology at the Cleveland Clinic, was widely quoted in news reports about the FDA advisory panels evaluating two new highly promising cholesterol drugs from Amgen and Sanofi/Regeneron. Nissen was broadly supportive of […]

Read More »

Exclusive: Alzheimer’s group may scrap early look at highly sought Lilly data

The Alzheimer’s Association may not offer an early look at highly sought clinical trial data on an experimental drug from Eli Lilly and Co (LLY.N) after news of the impending release led to a jump in the company’s shares. The influential patient group had been expected to post abstracts containing detailed trial findings on its […]

Read More »

Why Is Amgen Rising And Regeneron Falling?

An FDA advisory panel voted 11-4 Thursday to recommend a new type of cholesterol-lowering drug from Amgen (AMGN), but suggested limiting use to patients with a high risk of cardiovascular disease. Sound familiar? Regeneron (REGN) got similar treatment from the same panel yesterday, with advisers voting 13 to 3 to recommend approval of the experimental […]

Read More »

Lilly shares sizzle as investors await Alzheimer’s data

Shares of Eli Lilly and Co have jumped 10 percent this week, confounding many industry experts, amid speculation investors were placing bets ahead of expected long-term data on an Alzheimer’s disease treatment once considered a dud. With those gains, Lilly shares have leaped 26 percent for the year to date, eclipsing a 10 percent gain […]

Read More »

Bayer Dumps Diabetes Care Biz for $1.15 Billion

German pharma giant Bayer AG (BAYZF) will sell its diabetes business to Panasonic’s healthcare unit for around $1.15 billion, as the company begins shedding nonessential assets as part of a mission to refocus on life sciences. The deal will close in the first quarter of 2016, said the companies. The products included in the sale […]

Read More »

Receptos Allegedly Rebuffs AstraZeneca PLC Bid But Rivals Gilead, Teva are Circling

June 10, 2015By Mark Terry, Breaking News Staff It was reported yesterday by Proactive Investors’ Philip Waller that San Diego-based Receptos (RCPT) has rejected takeover bids by U.K.-based AstraZeneca PLC (AZN), Israel-based Teva Pharmaceutical Industries Ltd. (TEVA) and Foster City, Calif.-based Gilead Sciences, Inc. (GILD). Back in April 2015, Receptos announced that it had […]

Read More »

Mission Pharmacal Acquires ProSolus Pharmaceuticals

SAN ANTONIO, June 9, 2015 /PRNewswire/ — Effective May 29, 2015, Mission Pharmacal Company (“Mission”) has acquired the assets of ProSolus Pharmaceuticals LP headquartered in Miami, Fla. Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug delivery products to treat a variety of […]

Read More »

Celgene Shells Out $82.5 Million in Cash for Portfolio, Option to Buy Lycera

Ann Arbor, Mich.-based biopharma Lycera will license its RORgamma agonist to Celgene Corporation (CELG) as part of a $105-plus deal to create new cancer immunotherapies which also give Celgene the option to buy Lycera, the two companies announced Tuesday. Under the terms of the deal, Celgene will pay Lycera $82.5 million in cash up front, […]

Read More »

QLT Announces Multiple Transactions Designed to Transform the Company and Create Significant Near- and Long-Term Value for Shareholders

VANCOUVER, British Columbia–(BUSINESS WIRE)–QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT” or the “Company”) announced today that it has signed definitive agreements on multiple separate transformative transactions and will be returning capital to shareholders. Together, these actions are expected to create significant liquidity and near- and long-term value for QLT shareholders. InSite Vision Acquisition: QLT has entered into […]

Read More »

InSite Vision to Merge With Canadian Biotechnology Company QLT

ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB: INSV) today announced that it has reached a definitive agreement with QLT Inc. (NASDAQ: QLTI) (TSX: QLT) under which QLT will acquire InSite in an all-stock transaction that will create an ophthalmic specialty pharmaceutical company with a diversified portfolio of products, full R&D capabilities and innovative platform technologies. The […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom